Trial reportBMC psychiatry2025
Therapeutic effects of short-term trauma stabilization techniques combined with escitalopram in treating adolescent major depressive disorder: a pilot randomised controlled trial.
Trial report in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Efficacy and Safety of Escitalopram for Major Depressive Disorder in Children and Adolescents: A Systematic Review and Meta-Analysis with Age-Specific Findings.Neuropsychiatric disease and treatment · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo explore the efficacy of short-term trauma stabilization techniques combined with escitalopram in the treatment of adolescent major depressive disorder (MDD).
methodsA total of 80 patients with MDD who were hospitalized in the Psychosomatic Department of our hospital were selected and randomly divided into two groups: the escitalopram combined with short-term trauma stabilization technique group (study group) and the escitalopram combined with mental health education group (control group). Upon hospitalization, patients completed the adolescent self-rating life events check list (ASLEC), impact of event scale-revised (IES-R), 17-item Hamilton depression scale (HAMD-17) and Hamilton anxiety scale (HAMA). After 2 and 4 weeks of treatment, the IES-R, HAMD-17-17 and HAMA scores were reevaluated.
resultsThere were no significant differences in the ASLEC, IES-R, HAMD-17 or HAMA scores between the two groups at admission. Compared with that of the control group, the IES-R score of the study group was significantly improved at the 2nd week of treatment (P < 0.01). By the 4th week of treatment, the IES-R scores in the study group had further improved compared to the control group (P < 0.01). Additionally, the HAMD-17 and HAMA scores in the study group were significantly improved compared to the control group (P < 0.01).
conclusionEscitalopram combined with short-term trauma stabilization is more effective in the treatment of MDD than escitalopram with mental health education, warranting further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.